ABLIM1 promotes the proliferation, migration and invasion of osteosarcoma through DCC mediated activation of PI3K/AKT signaling pathway
Cellular Signalling · 2025
DOI: 10.1016/j.cellsig.2025.112077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2025. Verfasst von Qi Liao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China. Hauptthemen laut MEDLINE: Osteosarcoma, Proto-Oncogene Proteins c-akt, LIM Domain Proteins, Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Natural Science Foundation of Hubei Province, Wuhan University.
Abstract (Originalsprache)
BACKGROUND: Actin-binding LIM protein 1 (ABLIM1) is a member of the LIM domain protein family and has been identified as a novel E3 ubiquitin ligase. However, its precise biological function remains incompletely characterized. This study aimed to investigate the role of ABLIM1 in modulating the biological behavior of osteosarcoma cells and elucidate the underlying molecular mechanisms. METHODS: Through integrated bioinformatic analyses and experimental validation, we characterized ABLIM1 dysregulation in osteosarcoma and evaluated its prognostic significance. To determine ABLIM1's impact on osteosarcoma cell proliferation, migration, and invasion, we conducted comprehensive in vitro functional assays including CCK-8, EdU incorporation, wound healing, and Transwell invasion analyses. Subsequent investigation of ABLIM1-associated downstream pathways employed Western blotting and metabolic profiling, followed by rigorous validation experiments. Finally, we established a subcutaneous xenograft tumor model in nude mice to assess ABLIM1's in vivo functions. RESULTS: Silencing ABLIM1 significantly inhibited the proliferation, migration and invasion of osteosarcoma cells. On the contrary, overexpression of ABLIM1 resulted in the converse phenotype. In animal models, we injected silenced ABLIM1 143B osteosarcoma cells subcutaneously. The results showed that inhibiting the expression of ABLIM1 impaired the growth of osteosarcoma. CONCLUSION: Our research results indicate that ABLIM1 may be an independent prognostic factor for individuals diagnosed with osteosarcoma. By regulating the DCC/PI3K/AKT/mTOR axis, ABLIM1 promotes the growth, migration and invasion of osteosarcoma cells. Therefore, targeting ABLIM1 may serve as an effective therapeutic target for the treatment of osteosarcoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China.
- Wuhan University of Science and Technology, West Huangjiahu Road, Hongshan District, Wuhan 430065, China.
- Department of Thoracic Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430079, China. Electronic address: Wangjjchn@163.com.
- Department of Orthopedic Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China. Electronic address: ttyjgtk@163.com.
Förderung
- Natural Science Foundation of Hubei Province
- Wuhan University
Zitieren
APA
Liao, Q., Tong, S., Li, L., Wang, J., & Tong, K. (2025). ABLIM1 promotes the proliferation, migration and invasion of osteosarcoma through DCC mediated activation of PI3K/AKT signaling pathway. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2025.112077
Vancouver
Liao Q, Tong S, Li L, Wang J, Tong K. ABLIM1 promotes the proliferation, migration and invasion of osteosarcoma through DCC mediated activation of PI3K/AKT signaling pathway. Cellular Signalling. 2025. doi:10.1016/j.cellsig.2025.112077
BibTeX
@article{Liao2025,
author = {Liao, Qi and Tong, Siqi and Li, Lan and Wang, Jianjian and Tong, Kai},
title = {ABLIM1 promotes the proliferation, migration and invasion of osteosarcoma through DCC mediated activation of PI3K/AKT signaling pathway},
journal = {Cellular Signalling},
year = {2025},
doi = {10.1016/j.cellsig.2025.112077}
}
EUVIMED